Flow Diverter Versus Conventional Endovascular Treatment for Unruptured Wide-Neck Bifurcation Aneurysms (FD-BWA Trial)

Inclusion Criteria: 1. Age 18-75 years; 2. Diagnosis of unruptured intracranial, bifurcation, saccular, wide-neck aneurysm by DSA/CTA/MRA; 3. Patients who can understand the purpose of the trial, voluntarily participate and sign the informed consent form. Exclusion Criteria: 1. Patients with two or more multiple aneurysms that all require treatment within 1 year; 2. Concomitant cerebrovascular diseases such as arteriovenous malformation, moyamoya disease; 3. Ruptured aneurysms and narrow-neck aneurysms; 4. Patients who have had a stroke (cerebral hemorrhage, cerebral infarction) within the past 1 month; 5. Extremely poor clinical condition, modified Rankin Score ≥3; 6. Patients already scheduled for surgery/interventional procedure within 3 months; 7. Patients deemed unsuitable for interventional treatment by the investigator (e.g., no suitable vascular access, excessively tortuous vessels, difficulty delivering stent); 8. Patients unsuitable for anesthesia or endovascular surgery, such as major diseases of heart, lung, liver, spleen, kidney, brain tumors, severe active infections, disseminated intravascular coagulation, severe mental illness; 9. Patients unable to receive antiplatelet or anticoagulant therapy; 10. Patients who have had or may have severe reactions to contrast media precluding pre-treatment medication; 11. Patients with a definite history of allergy to cobalt-chromium, nickel-titanium alloy materials; 12. Participation in other drug or medical device clinical trials before enrollment without reaching the primary endpoint timeframe; 13. Pregnant or breastfeeding women; 14. Patient's life expectancy less than 12 months; 15. Investigator judges that the patient has poor compliance and cannot complete the study as required.